Astellas Pharma Inc.-Unsp ADRALPMY
13F holders, Q3 2025 (September 30)8holders
1new positions
1sold out
$10.87avg. 13F price*
At the end of Q3 2025, 8 institutions reported holding Astellas Pharma Inc.-Unsp ADR (ALPMY) in their 13F filings, unchanged from Q2 2025. 1 opened new positions and 1 sold out. The largest holders were Hantz Financial Services, Inc. ($2.5M), Lanark Financial, Inc. ($618K) and Rhumbline Advisers ($270K).
- Company
- Astellas Pharma Inc.-Unsp ADR
- CUSIP
- 04623U102
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $3K |
| Exits | 1 | $22K |
All 13F filers, Q2 2025 → Q3 2025: 75,071 shares bought and 8,521 shares sold, net +66,550 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 8 holders
| Hantz Financial Services, Inc. | 0.04% | Add +36.2% | 225,194 | $2.5M |
| Lanark Financial, Inc. | 0.05% | Add +28.1% | 57,055 | $618K |
| Rhumbline Advisers | 0.00% | Reduce -20.2% | 24,846 | $270K |
| GAMMA Investing LLC | 0.01% | Add +21.9% | 8,740 | $95K |
| Salomon & Ludwin, LLC | 0.00% | Add +4438.9% | 817 | $9K |
| Steigerwald, Gordon & Koch Inc. | 0.00% | New | 301 | $3K |
| Wealth Preservation Advisors, LLC | 0.00% | No change | 224 | $2K |
| PNC Financial Services Group, Inc. | 0.00% | No change | 56 | $609 |
"% of holder's portfolio" is ALPMY's weight in each manager's 13F, not the share of Astellas Pharma Inc.-Unsp ADR the manager owns.